TNF and diverticulitis: One study reported an elevated risk of diverticulitis during TCZ treatment compared with TNF inhibitors (HR 2.34, 95% CI 1.64 to 3.34).108 Higher rates of any GI infections were observed with TCZ compared with ETN as reference compound in another study (HR 1.45, 95% CI 0.72 to 2.90).107 Similarly, a conference abstract assessed the risk of diverticulitis in patients with RA: three prospective observational French registries, confirmed an elevated risk of diverticulitis for TCZ compared with RTX-treated or ABA-treated patients.119